AR068538A1 - Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido - Google Patents

Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido

Info

Publication number
AR068538A1
AR068538A1 ARP080104134A ARP080104134A AR068538A1 AR 068538 A1 AR068538 A1 AR 068538A1 AR P080104134 A ARP080104134 A AR P080104134A AR P080104134 A ARP080104134 A AR P080104134A AR 068538 A1 AR068538 A1 AR 068538A1
Authority
AR
Argentina
Prior art keywords
atom
group
ring
optionally substituted
nitrogen atom
Prior art date
Application number
ARP080104134A
Other languages
English (en)
Inventor
Keizo Hirase
Yasuyoshi Arikawa
Haruyuki Nishida
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR068538A1 publication Critical patent/AR068538A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente provee un compuesto representado por la formula (1) en donde el anillo A es un heterociclo saturado o insaturado de 5 miembros que contiene como átomo constituyente del anillo, además de átomos de carbono, al menos un heteroátomo seleccionado de un átomo de nitrogeno, un átomo de oxígeno y un átomo de azufre, los átomos constituyentes del anillo X1 y X2 son iguales o diferentes y cada uno es un átomo de carbono o un átomo de nitrogeno, los átomos constituyentes del anillo X3 y X4 son iguales o diferentes y cada uno es un átomo de carbono, un átomo de nitrogeno, un átomo de oxígeno o un átomo de azufre (con la condicion de que se excluya un anillo pirrol en donde X1 es un átomo de nitrogeno del anillo A) y cuando los átomos constituyentes del anillo X3 y X4 son iguales o diferentes y cada uno es un átomo de carbono o un átomo de nitrogeno, cada átomo constituyente del anillo tiene opcionalmente sustituyentes seleccionados de un grupo alquilo opcionalmente sustituido, un grupo acilo, un grupo hidroxi opcionalmente sustituido, un grupo mercapto opcionalmente sustituido, un grupo amino opcionalmente sustituido, un átomo de halogeno, un grupo ciano y un grupo nitro; el anillo B es un grupo cíclico que contiene X5 y X6 como átomos constituyentes del anillo, X5 es un átomo de carbono o un átomo de nitrogeno y X6 es un átomo de carbono, un átomo de nitrogeno, un átomo de oxígeno o un átomo de azufre; R1 es un grupo cíclico que opcionalmente tiene sustituyente; R2 es un sustituyente que tiene opcionalmente X6 cuando X6 es un átomo de carbono o un átomo de nitrogeno; R3 es un grupo alquilo opcionalmente sustituido, un grupo acilo, un grupo hidroxi opcionalmente sustituido, un grupo mercapto opcionalmente sustituido, un grupo amino opcionalmente sustituido, un átomo de halogeno, un grupo ciano o un grupo nitro; R4 y R5 son iguales o diferentes y cada uno es un átomo de hidrogeno o un grupo alquilo, o R4 y R5 forman opcionalmente, junto con el átomo de nitrogeno adyacente, un heterociclo opcionalmente sustituido que contiene nitrogeno; m es 0 o 1, con la condicion de que cuando el anillo B es un grupo arilo o un grupo heteroarilo, entonces m sea 1; y n es un numero entero de 0 a 3, o una de sus sales. El presente compuesto tiene un efecto inhibidor de la secrecion de ácidos superior y muestra una actividad antiulcera y similares. Profármacos, agente farmacéutico y uso.
ARP080104134A 2007-09-28 2008-09-24 Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido AR068538A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007256274 2007-09-28
JP2008218076 2008-08-27

Publications (1)

Publication Number Publication Date
AR068538A1 true AR068538A1 (es) 2009-11-18

Family

ID=40512007

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104134A AR068538A1 (es) 2007-09-28 2008-09-24 Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido

Country Status (9)

Country Link
US (1) US20090156642A1 (es)
EP (1) EP2190822B1 (es)
JP (1) JP5345140B2 (es)
KR (1) KR101558011B1 (es)
AR (1) AR068538A1 (es)
CL (1) CL2008002834A1 (es)
PE (1) PE20090709A1 (es)
TW (1) TW200920366A (es)
WO (1) WO2009041705A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5379690B2 (ja) * 2007-09-28 2013-12-25 武田薬品工業株式会社 ５員複素環化合物
SG186685A1 (en) 2008-07-28 2013-01-30 Takeda Pharmaceutical Pharmaceutical composition
EP2318390B1 (en) 2008-08-27 2013-05-01 Takeda Pharmaceutical Company Limited Pyrrole compounds
EP2412713B1 (en) 2009-03-26 2016-11-30 Takeda Pharmaceutical Company Limited Pyrazole compound
KR101605063B1 (ko) 2009-07-09 2016-03-21 라퀄리아 파마 인코포레이티드 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
CN110917130A (zh) 2012-06-27 2020-03-27 武田药品工业株式会社 用盐稳定的胺和有机酸的液体制剂
WO2014144878A2 (en) * 2013-03-15 2014-09-18 The Scripps Research Institute Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
CN108191829B (zh) * 2016-06-30 2020-07-03 珠海赛隆药业股份有限公司（长沙）医药研发中心 应用富马酸沃诺拉赞中间体ⅳ制备富马酸沃诺拉赞的方法
CN108203430A (zh) * 2016-12-16 2018-06-26 天地人和生物科技有限公司 一种新型可逆性质子泵抑制剂及其制备方法和用途
KR102537983B1 (ko) 2017-04-24 2023-05-31 바이엘 악티엔게젤샤프트 해충 방제제로서의 축합된 비시클릭 헤테로시클릭-화합물 유도체
CN112830920A (zh) * 2019-11-25 2021-05-25 杭州华东医药集团新药研究院有限公司 一种杂环衍生物、其药物组合物及用途
GB201919213D0 (en) 2019-12-23 2020-02-05 Ucb Biopharma Sprl Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
CN113620930B (zh) * 2021-07-12 2022-08-16 南京烁慧医药科技有限公司 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3285991A (en) * 1963-03-26 1966-11-15 Union Carbide Corp Polyepoxides cured with the reaction product of a dihydroxydiphenylsul-fone, an amine, and an aldehyde
ES2211917T3 (es) * 1994-09-26 2004-07-16 SHIONOGI & CO., LTD. Derivado de imidazol.
EP1534278A4 (en) * 2002-08-01 2006-09-06 Nitromed Inc NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
ATE482933T1 (de) * 2003-05-26 2010-10-15 Takeda Pharmaceutical Sulfopyrrolderivate
EP2336107B1 (en) * 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Proton pump inhibitors
FR2881744B1 (fr) * 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
DK1919865T3 (da) * 2005-08-30 2011-05-23 Takeda Pharmaceutical 1-Heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl-substituerede 1-h-pyrrolderivater som syresekretionsinhibitorer
FR2894578B1 (fr) * 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
EP2005957B1 (en) * 2006-03-31 2012-05-30 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
JP5379690B2 (ja) * 2007-09-28 2013-12-25 武田薬品工業株式会社 ５員複素環化合物

Also Published As

Publication number Publication date
WO2009041705A3 (en) 2009-06-25
TW200920366A (en) 2009-05-16
US20090156642A1 (en) 2009-06-18
KR101558011B1 (ko) 2015-10-06
WO2009041705A9 (en) 2009-08-13
WO2009041705A2 (en) 2009-04-02
PE20090709A1 (es) 2009-07-15
JP2010540412A (ja) 2010-12-24
JP5345140B2 (ja) 2013-11-20
EP2190822B1 (en) 2014-12-31
CL2008002834A1 (es) 2009-09-11
EP2190822A2 (en) 2010-06-02
KR20100080544A (ko) 2010-07-08

Similar Documents

Publication Publication Date Title
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
CO2020009567A2 (es) Inhibidores de monoacilglicerol lipasa (magl) de oxazina
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
PE20040373A1 (es) Composiciones herbicidas que comprenden derivados de isoxazolina
AR048669A1 (es) Derivados biciclicos de bisamida
SV2010003459A (es) Derivados de pirimidina 934
PH12015501934A1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR066583A1 (es) Derivados de 3,3-espiroindolinona
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas
AR061994A1 (es) Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden
AR077818A1 (es) Composiciones pesticidas
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
RS52562B (en) (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
BR112015029182A2 (pt) composto para uso em modulação da rota wnt, uso do composto, método, composição farmacêutica, forma anidra, uso de uma base livre anidra
CO2019002692A2 (es) Nuevos derivados de isoxazolil éter como pam de gaba a alfa5.
UA117151C2 (uk) N-ациліміногетероциклічні сполуки
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
AR103266A1 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR066605A1 (es) Derivados de heteroarilamida pirimidona
ES2578628T3 (es) Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4
CO2018010787A2 (es) Compuesto de griseofulvina
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb

Legal Events

Date Code Title Description
FB Suspension of granting procedure